Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

被引：0
|
作者：
Duan, J. C. [1 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; Third Generation EGFR-TKI; Resistance Mechanism;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-29
引用
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [21] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
    Sakai, Hiroshi
    Kishi, Kazuma
    Seto, Takashi
    Kozuki, Toshiyuki
    Nishio, Makoto
    Imamura, Fumio
    Nokihara, Hiroshi
    Satouchi, Miyako
    Tahata, Takashi
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
  • [22] EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy
    Hulo, Pauline
    Coupez, Dahna
    Denis, Marc G.
    Bennouna, Jaafar
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (05) : 365 - 372
  • [23] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
    Lin, G.
    Chu, Q.
    Huang, L.
    Wu, L.
    Yu, Y.
    Liu, Z.
    Huang, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S663 - S663
  • [25] Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
    Wang, J.
    Cheng, Y.
    Wu, Y.
    An, T.
    Gao, H.
    Wang, K.
    Zhou, Q.
    Hu, Y.
    Song, Y.
    Ding, C.
    Peng, F.
    Liang, L.
    Hu, Y.
    Huang, C.
    Zhou, C.
    Shi, Y.
    Zhang, L.
    Ye, X.
    Sun, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1844 - S1844
  • [26] A PHASE II STUDY OF ERLOTINIB AS FIRST-LINE TREATMENT IN JAPANESE ADVANCED NSCLC PATIENTS HARBORING EGFR MUTATIONS
    Horiike, A.
    Nishio, M.
    Goto, K.
    Yamamoto, N.
    Chikamori, K.
    Maemondo, M.
    Hida, T.
    Katakami, N.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 413 - 413
  • [27] First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases
    Zang, L.
    Wang, H. T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S645 - S646
  • [28] Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
    Ng, I.
    Kumarakulasinghe, N.
    Syn, N.
    Teng, R.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2208 - S2209
  • [29] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [30] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
12345